DexCom (DXCM) is back in focus after Health Canada authorized the Dexcom G7 15 Day continuous glucose monitoring system, extending approved sensor wear to 15.5 days for adults with diabetes.

At a share price of $71.54, DexCom has seen a 20.6% 90 day share price return even as the 1 year total shareholder return is down 20.1%. This suggests recent momentum has improved while longer term holders still sit on losses.

If this kind of regulatory catalyst has your attention, it could be a good moment to scan for other healthcare companies using AI in meaningful ways through the 40 healthcare AI stocks

DexCom’s 20.6% 90 day rebound now sits against a share price that is below both analyst targets and an estimated fair value. Is this a gap worth leaning into, or is the market’s caution still doing useful work?

Most Popular Narrative: 16.1% Undervalued

With DexCom closing at $71.54 against a most-followed fair value estimate of $85.24, the current price sits well below that narrative benchmark, which leans heavily on long term CGM adoption and margin assumptions.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion.

Curious what underpins that $85.24 fair value for DexCom? The narrative leans on sustained double digit growth, thicker margins and a future earnings multiple that assumes CGM remains a core tool in diabetes care. The specific revenue path, margin profile and valuation multiple doing the heavy lifting here are all laid out, step by step, inside the full narrative.

Result: Fair Value of $85.24 (UNDERVALUED)

However, DexCom’s story could change quickly if proposed Medicare competitive bidding pressures CGM pricing, or if rising competition in sensors starts to squeeze margins and share.

Another View: DexCom Through a Market Multiple Lens

While the SWS DCF model points to DexCom trading at a discount to estimated future cash flows, the market is less generous when you look at simple earnings multiples. DexCom trades on a P/E of 29.7x, above the US Medical Equipment industry at 26.7x and a peer average of 24.7x, although slightly below its fair ratio of 31.6x. That mix of premium pricing and modest headroom against the fair ratio raises a basic question for investors: is the market already paying up for much of DexCom’s story, or is there still mispriced upside hiding in the gap?

Next Steps

If the mix of optimism and caution around DexCom leaves you undecided, review the details promptly and form your own judgment using the 4 key rewards

Looking for more investment ideas beyond DexCom?

Do not stop with DexCom. Broaden your watchlist now and give yourself more options, before the next wave of opportunities moves without you.

• Target resilience by scanning companies that emphasise financial strength and steady fundamentals through the solid balance sheet and fundamentals stocks screener (49 results)
• Hunt for pricing gaps where quality and valuation might line up using the 50 high quality undervalued stocks
• Stack potential income streams alongside growth ideas by reviewing the 9 dividend fortresses

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.